Sweden's Camurus Q3 revenue beats estimates on Buvidal, Brixadi growth

By Reuters News


Overview

  • Sweden biopharma firm's Q3 revenue rose 28% yr/yr, beating analyst expectations

  • Q3 operating profit grew 40% yr/yr

  • Company reiterated 2026 outlook, expects results in upper half of guided ranges


Outlook

  • Camurus expects 2026 revenues in the upper half of BNSEK 2.6-2.9 guidance range

  • Company sees 2026 operating result in the upper half of BNSEK 0.9-1.2 guidance range

  • FDA decision on CAM2029 for acromegaly expected by 18 December, 2026


Result Drivers

  • BUVIDAL AND BRIXADI GROWTH - Co said record product sales were driven by continued growth for Buvidal and higher Brixadi royalties

  • NO MILESTONE REVENUE - Co noted that Q3 results were achieved without milestone revenue contributions

  • REGULATORY PROGRESS - Co highlighted FDA review of CAM2029 and Australian approval of Oczyesa as key developments in the quarter


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

SEK 724 mln

SEK 691.20 mln (5 Analysts)

Q3 EBIT

SEK 322 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Camurus AB is SEK780.00, about 17.3% above its November 4 closing price of SEK665.00

  • The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 29 three months ago


Reuters Recommended Reads

  • Nov 4 - Novo loses share in Brazil to cheaper generics, but holds up in Canada and India

  • Nov 4 - Novo Nordisk Q3 adjusted profit, sales jump on GLP-1 demand; raises outlook

  • Nov 2 - Travere Q3 product sales nearly double on FILSPARI growth


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk